{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:54:17Z","timestamp":1792688057091,"version":"4.5.0"},"reference-count":11,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Autoimmune-related adverse effects may occur from monoclonal antibody medications though autoimmune encephalopathy is not a commonly reported reaction. Inhibiting the insulin-like growth factor 1 pathway has been shown to cause neurocognitive side effects. We report a case of a man in his early 60s who presented with neuropsychiatric changes after beginning teprotumumab for thyroid eye disease. He was diagnosed with teprotumumab-induced encephalopathy and ultimately treated with plasma exchange.<\/jats:p>","DOI":"10.1136\/bcr-2025-271752","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:25:44Z","timestamp":1778246744000},"page":"e271752","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["From orbit to cortex: recognising teprotumumab-induced encephalopathy"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2683-4185","authenticated-orcid":false,"given":"Alan","family":"Spicer","sequence":"first","affiliation":[{"name":"College of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3349-5205","authenticated-orcid":false,"given":"Zuhair","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Lehigh Valley Health Network, Allentown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Hao","family":"Yang","sequence":"additional","affiliation":[{"name":"Lehigh Valley Health Network, Allentown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Punati","sequence":"additional","affiliation":[{"name":"Lehigh Valley Health Network, Allentown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-7593","authenticated-orcid":false,"given":"Connie","family":"Tang","sequence":"additional","affiliation":[{"name":"Lehigh Valley Health Network, Allentown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026050806251224000_19.5.e271752.1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad213"},{"key":"2026050806251224000_19.5.e271752.2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/NAN.0000000000000446","article-title":"Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects","volume":"44","author":"Kang","year":"2021","journal-title":"J Infus Nurs"},{"key":"2026050806251224000_19.5.e271752.3","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1038\/s41380-023-02136-6","article-title":"The neurobiology of insulin-like growth factor I: From neuroprotection to modulation of brain states","volume":"28","author":"Nu\u00f1ez","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026050806251224000_19.5.e271752.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04457-1"},{"key":"2026050806251224000_19.5.e271752.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713301"},{"key":"2026050806251224000_19.5.e271752.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.1"},{"key":"2026050806251224000_19.5.e271752.7","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01927-17","article-title":"Evaluation of a Commercial Multiplex Molecular Panel for Diagnosis of Infectious Meningitis and Encephalitis","volume":"56","author":"Liesman","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026050806251224000_19.5.e271752.8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"},{"key":"2026050806251224000_19.5.e271752.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2026050806251224000_19.5.e271752.10","first-page":"134","article-title":"Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic","volume":"122","author":"Yee","year":"2023","journal-title":"WMJ"},{"key":"2026050806251224000_19.5.e271752.11","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:25:45Z","timestamp":1778246745000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bcr-2025-271752"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271752","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}